Global markets for osteoporosis drugs and technologies to reach $9.7 billion by 2014

The global market for drugs that treat and prevent osteoporosis declined to $8 billion in 2009 (as compared to $8.4 billion in 2008), but is expected to grow to $9.7 billion in 2014, showing a compound annual growth rate (CAGR) of 3.8% between 2009 and 2014.

Learn about the osteoporosis drugs currently on the market in six major classes; get an analysis of the market trends through 2014 along with a breakdown of the industry structure and comprehensive company profiles...

Use this report to:

• Receive an understanding of the global market for prescription drugs that treat and prevent osteoporosis focusing on industry structure and major participants in the osteoporosis drugs market, market dynamics and competitive aspects, current developments and future market trends to assist in understanding the market and identifying areas of commercial interest and potential in osteoporosis
• Understand and assess the current market status along with an analysis of the patient population, marketed drugs, market revenues, and company shares
• See 5 year future market revenue forecasts for the global market, major drug classes and the largest geographical regions, as well as the reviews of the compounds being investigated in clinical studies for the treatment of osteoporosis from 2009 through 2014
• Determine future developments in the osteoporosis drugs market covering the period from 2007 through 2014, while describing the existing drug classes approved for these indications, including bisphosphonates, selective estrogen receptor modulators (SERMS), parathyroid hormones (PTHs), calcitonins, dual-action bone agents (DABAs), and hormone replacement therapies (HRTs).

To provide further information about this report we offer a Complimentary Introduction, available from our Website. To download, simply click here, go to the Table of Contents tab, add the complimentary introduction to your cart, and confirm your order.